CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies
Sirius Therapeutics Announces Nearly $50 million Financing to Accelerate Clinical Development of siRNA Therapeutics for Cardiometabolic Diseases
Sirius Therapeutics announces U.S. FDA Clearance of IND to Begin Clinical Trial of Novel siRNA Therapy for Hyperlipoproteinemia(a)
TRexBio Expands Leadership Team with Appointments of Ariella Kelman, M.D., as Chief Medical Officer and Brandon Hants, MBA, as Chief Financial Officer
Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer
Ensoma Receives Rare Pediatric Disease and Orphan Drug Designations for EN-374 for Treatment of Chronic Granulomatous Disease
Rejoni completes patient enrollment in pivotal clinical study of a Novel Treatment for the Prevention of Intrauterine Adhesions, the Juveena® Hydrogel System.
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug Conjugate
